Carmell Therapeutics Corporation
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on … Read more
Carmell Therapeutics Corporation (CTCX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: 0.198x
Based on the latest financial reports, Carmell Therapeutics Corporation (CTCX) has a cash flow conversion efficiency ratio of 0.198x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-752.95K) by net assets ($-3.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Carmell Therapeutics Corporation - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Carmell Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Carmell Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carmell Therapeutics Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Noronex Ltd
AU:NRX
|
-1.946x |
|
Anik Industries Limited
NSE:ANIKINDS
|
-0.051x |
|
Era Mandiri Cemerlang Tbk PT
JK:IKAN
|
0.073x |
|
NSBBF
OTCQB:NSBBF
|
0.071x |
|
XWELL Inc.
NASDAQ:XWEL
|
-0.687x |
|
Wahana Pronatural
JK:WAPO
|
0.002x |
|
Gasporox AB (publ)
ST:GPX
|
-0.009x |
|
Ronin Resources Ltd
AU:RON
|
0.000x |
Annual Cash Flow Conversion Efficiency for Carmell Therapeutics Corporation (2021–2024)
The table below shows the annual cash flow conversion efficiency of Carmell Therapeutics Corporation from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.71 Million | $-4.39 Million | 0.931x | +376.10% |
| 2023-12-31 | $24.75 Million | $-8.35 Million | -0.337x | -471.78% |
| 2022-12-31 | $-37.79 Million | $-3.43 Million | 0.091x | +128.03% |
| 2021-12-31 | $-29.58 Million | $-1.18 Million | 0.040x | -- |